July 28, 2015European Heart Journal1,171 citationsOpen Access

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction

EGEsther González-López MGMaría Gallego‐Delgado GGGonzalo Guzzo-Merello

Structured PICO

Population

Patients with heart failure with preserved ejection fraction (HFpEF)

Wild-type transthyretin amyloidosis is an underdiagnosed condition that accounts for a significant proportion (13%) of HFpEF cases.

Abstract

ATTRwt is an underdiagnosed disease that accounts for a significant number (13%) of HFpEF cases. The effect of emerging TTR-modifying drugs should be evaluated in these patients.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

González-López et al. (2015) studied this question.

synapsesocial.com/papers/69aea5047defb997d5abdda7 https://doi.org/10.1093/eurheartj/ehv338

Ask AI

Helpful

Bookmark

View Full Paper

July 28, 2015European Heart Journal1,171 citationsOpen Access

Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction

View Full Paper

EGEsther González-López MGMaría Gallego‐Delgado GGGonzalo Guzzo-Merello

Structured PICO

Population

Patients with heart failure with preserved ejection fraction (HFpEF)

Wild-type transthyretin amyloidosis is an underdiagnosed condition that accounts for a significant proportion (13%) of HFpEF cases.

Abstract

ATTRwt is an underdiagnosed disease that accounts for a significant number (13%) of HFpEF cases. The effect of emerging TTR-modifying drugs should be evaluated in these patients.

Ask AI

Helpful

Bookmark

View Full Paper

Cite This Study

González-López et al. (2015) studied this question.

synapsesocial.com/papers/69aea5047defb997d5abdda7 https://doi.org/10.1093/eurheartj/ehv338

Ask AI

Helpful

Bookmark

View Full Paper